EGFR and glioblastoma: EGFR parameters are regularly included when profiling the molecular background of GBM samples and although aberrant EGFR is common and actionable in extracranial primary malignancies, very few patients with GBM respond to EGFR tyrosine kinase inhibitors (TKIs).